Voclosporin

證據等級: L5

預測適應症: 10 個

A few data-quality notes before the report: drug.original_indications is empty and original_moa is [Data Gap], so no specific original indication is documented in this pack. The evidence pack’s own literature/rationale text (not the original_moa field) does establish that voclosporin is a calcineurin-inhibitor immunosuppressant — I’ve used that only where it’s explicitly sourced from the pack’s literature/rationale content, and flagged everywhere else that data is missing, per the “no fabrication” rule.

Voclosporin: From Immunosuppressive Therapy to Primary Release Disorder of Platelets

One-Sentence Summary

Voclosporin is a calcineurin-inhibitor immunosuppressant (class-mate of cyclosporine and tacrolimus); no specific original approved indication is documented in this evidence pack, and the drug is not currently marketed in Denmark. The TxGNN model’s top-ranked prediction links it to Primary Release Disorder of Platelets, with a 95.4% prediction score, but zero supporting clinical trials and zero literature, and the model’s own mechanistic rationale states this link is biologically implausible.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no `original_indications` on file; drug not yet marketed in Denmark)
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	95.42%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for voclosporin is not available at the drug level in this evidence pack (original_moa: [Data Gap]). However, the literature and rationale entries attached to other candidate indications in this same pack indicate that voclosporin belongs to the calcineurin-inhibitor (CNI) class, alongside cyclosporine and tacrolimus. According to a review captured in this pack (PMID 41361657), CNIs act by inhibiting the calcium-dependent phosphatase calcineurin, blocking dephosphorylation/nuclear translocation of NFAT, and suppressing IL-2 transcription — thereby impairing T-cell activation. This is standard immunosuppressant pharmacology, not a validated original indication for voclosporin specifically.

For the model’s top-ranked prediction — primary release disorder of platelets — the evidence pack’s own mechanistic assessment is explicitly negative: this is a hereditary defect in platelet dense-granule secretion, a structural/genetic platelet disorder with pathophysiology unrelated to T-cell activation or the calcineurin pathway. The pack states plainly that “目前無任何臨床或文獻證據支持” (no clinical or literature evidence currently supports this) and classifies the association as a prediction-only artifact that “未達可驗證假說門檻” (has not reached the threshold of a testable hypothesis).

In short: the TxGNN similarity score (95.4%) is high, but the accompanying rationale — generated from the same evidence pack — does not corroborate a plausible biological mechanism. A high embedding-similarity score without mechanistic or empirical support should be interpreted cautiously; it may reflect graph-clustering effects among platelet-related disease nodes rather than a genuine pharmacological relationship.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Voclosporin currently has no marketing authorisation on file in Denmark (market_status: Not marketed; total_licenses: 0). No Laegemiddelstyrelsen national authorisation or EMA centralised authorisation record is present in this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

(Note: this evidence pack’s own data-gap log flags the missing label/warning data — item DG001, “TFDA 仿單警語/禁忌” — as a Blocking severity gap, meaning this candidate cannot yet proceed to the safety-review stage (S1) until label data is retrieved.)

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence level is L5 — model prediction only, with no clinical trials, no literature, and no observational data supporting a link between voclosporin and primary release disorder of platelets.
The evidence pack’s own mechanistic rationale explicitly contradicts biological plausibility: platelet dense-granule secretion defects are not known to involve the calcineurin/T-cell activation pathway that voclosporin targets.
Two data gaps block further progression: DG001 (Danish/EU SmPC warnings and contraindications — Blocking, prevents entry to safety-review stage S1) and DG002 (confirmed mechanism of action — High, needed for mechanistic validation).

To proceed, the following is needed:

Retrieve the approved SmPC (Danish/EU label) for voclosporin to resolve DG001 before any safety review can begin
Confirm mechanism of action via DrugBank or primary pharmacology sources to resolve DG002
Any preclinical or mechanistic literature directly linking calcineurin inhibition to platelet dense-granule release would be required before this candidate could move beyond Hold
For consideration: this same evidence pack contains a lower-ranked but better-supported candidate — dermatitis (TxGNN score 94.2%, evidence level L3, decision stage S1 “Research Question”) — backed by 2 literature reviews (PMID 37307993, PMID 41361657) discussing off-label dermatologic use of systemic calcineurin inhibitors including voclosporin. That candidate has a coherent class-effect mechanistic rationale and may warrant prioritized follow-up ahead of the top-ranked but mechanistically unsupported platelet-disorder prediction.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.